Special Considerations in the Management of Women With HIV, Including Management of Conception and Pregnancy
Summary
- All combined hormonal contraceptive methods and intrauterine devices are listed as Category 1 (no restriction for use) for women at high risk for HIV or with HIV or AIDS by the CDC Medical Eligibility Criteria for Contraceptive Use[Tepper 2020] Efavirenz may decrease etonogestrel and levonorgestrel levels attained from implants[DHHS Perinatal; ref:Leticee 2012; Scarsi 2016]
- Cobicistat may increase estrogen and progestin levels[Nanda 2017]
- Ritonavir may decrease or increase progestin levels depending on the specific contraceptive used[Nanda 2017]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Drug-Drug Interactions, Pregnancy, Women